Zobrazeno 1 - 10
of 126
pro vyhledávání: '"Sandeep, Sahay"'
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 4, Pp n/a-n/a (2023)
Abstract Pulmonary hypertension secondary to left‐sided valvular disease (VHD‐PH) is associated with high morbidity and mortality. Angiotensin‐receptor neprilysin inhibitor (ARNI) is a novel pharmacotherapy, which reduces afterload with natriur
Externí odkaz:
https://doaj.org/article/70af35b3ec3b42df8942a2fadca2396a
Autor:
Kellie Morland, Christian Gerges, Jean Elwing, Scott H. Visovatti, Jason Weatherald, Kari R. Gillmeyer, Sandeep Sahay, Stephen C. Mathai, Athénaïs Boucly, Paul G. Williams, Sivadasanpillai Harikrishnan, Evan P. Minty, Lukas Hobohm, Arun Jose, Roberto Badagliacca, Edmund M. T. Lau, Zhi‐Cheng Jing, Rebecca R. Vanderpool, Charles Fauvel, Jose Leonidas Alves Jr., Geoff Strange, Tomas Pulido, Junyan Qian, Mengtao Li, Valentina Mercurio, Jason G. E. Zelt, Victor M. Moles, Meghan M. Cirulis, Sylvia M. Nikkho, Raymond L. Benza, C. Gregory Elliott
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 4, Pp n/a-n/a (2023)
Abstract This manuscript on real‐world evidence (RWE) in pulmonary hypertension (PH) incorporates the broad experience of members of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative Real‐World Evidence Working Gr
Externí odkaz:
https://doaj.org/article/cbfc593f3e3c499eb6df1025f764229f
Autor:
Nidhy P. Varghese, Akhilesh A. Padhye, Pilar L. Magoulas, George B. Mallory, Fadel E. Ruiz, Sandeep Sahay
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 3, Pp n/a-n/a (2023)
Abstract Heritable pulmonary artery hypertension (HPAH) is an increasingly recognized type of pulmonary arterial hypertension, in both pediatric and adult population. Intrinsic to hereditary disease, screening for genetic mutations within families is
Externí odkaz:
https://doaj.org/article/606616355a4c4ac1a9e6bb7463e9f388
Autor:
Rodolfo A. Estrada, Sandeep Sahay
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 2, Pp n/a-n/a (2023)
Externí odkaz:
https://doaj.org/article/27e33f5925fe4ee2a41da0c6fd237001
Autor:
Kahtan Fadah, Jose B. Cruz Rodriguez, Haider Alkhateeb, Debabrata Mukherjee, Hernando Garcia, Dan Schuller, Khan O. Mohammad, Sandeep Sahay, Nils P. Nickel
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 2, Pp n/a-n/a (2023)
Abstract Pulmonary arterial hypertension (PAH) is a cardiovascular disease with high mortality rate. Current guidelines propose initiation and escalation of PAH‐targeted treatment based on a goal‐directed approach targeting hemodynamic, functiona
Externí odkaz:
https://doaj.org/article/ab4e5d243a8f40d1956196510ee62745
Autor:
Jacob DeBerry, Parth Rali, Michael McDaniel, Christopher Kabrhel, Rachel Rosovsky, Roman Melamed, Oren Friedman, Jean M. Elwing, Vijay Balasubramanian, Sandeep Sahay, Eduardo Bossone, Mary Jo S. Farmer, Andrew J. P. Klein, Megan E. Hamm, Charles B. Ross, Belinda N. Rivera-Lebron
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundInterhospital transfer (IHT) of patients with acute life-threatening pulmonary embolism (PE) is necessary to facilitate specialized care and access to advanced therapies. Our goal was to understand what barriers and facilitators may exist d
Externí odkaz:
https://doaj.org/article/75aab6db92144cddab7123221e778e61
Autor:
Nicholas S. Hill, Jeremy P. Feldman, Sandeep Sahay, Raymond L. Benza, Ioana R. Preston, David Badesch, Robert P. Frantz, Savan Patel, Ashley Galloway, Todd M. Bull, the INSPIRE study investigators
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 3, Pp n/a-n/a (2022)
Abstract The INSPIRE trial was a Phase 3, open‐label, multicenter trial (LTI‐301) that enrolled patients with pulmonary arterial hypertension (PAH) ≥ 18 years of age who transitioned to Yutrepia from nebulized treprostinil (Transition) or added
Externí odkaz:
https://doaj.org/article/d3d486acf448475aa616783826502355
Autor:
Sandeep Sahay, Vijay Balasubramanian, Humna Memon, Abby Poms, Eduardo Bossone, Kristine Highland, Dana Kay, Deborah J Levine, Christopher J Mullin, Lana Melendres‐Groves, Stephen C Mathai, Francisco J Soto, Oksana Shlobin, Jean M Elwing
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Pulmonary arterial hypertension (PAH) is a chronically progressive fatal disease. A goal‐oriented approach to achieve low risk status has been associated with improved survival. A variety of risk stratification tools are available, but use
Externí odkaz:
https://doaj.org/article/10dc882d91c940ca9de32b077a366fb3
Autor:
Leslie A. Spikes, Abubakr A. Bajwa, Charles D. Burger, Sapna V. Desai, Michael S. Eggert, Karim A. El‐Kersh, Micah R. Fisher, Shilpa Johri, Joanna M. Joly, Jinesh Mehta, Harold I. Palevsky, Gautam V. Ramani, Ricardo Restrepo‐Jaramillo, Sandeep Sahay, Trushil G. Shah, Chunqin Deng, Melissa Miceli, Peter Smith, Shelley M. Shapiro
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Inhaled treprostinil is an approved therapy for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease in the United States. Studies have confirmed the robust benefits and safety of nebuliz
Externí odkaz:
https://doaj.org/article/54bf8d2f543344f38ef9f1658923dfa4
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 1, Pp n/a-n/a (2022)
Abstract Pulmonary veno‐occlusive disease (PVOD) is a progressively fatal disease with no definitive treatment options. PVOD can be a result of genetic mutation but can also be due secondary to exposure to solvents or chemotherapeutic agents. Gener
Externí odkaz:
https://doaj.org/article/5f562114e5fa4b9abe771bb44a5b9e2e